XLY Analysis

The Consumer Discretionary Select Sector SPDR Fund (XLY)

Update 1/31/2020: I exited my short iron condor on XLY today, 21 days before expiration, for a $0.79 debit, a profit of $0.08 per contract share, at 9.2% of maximum potential profit. Shares were trading at $126.36, having risen $0.43 above the entry level.

XLY maintained a rising trend for 10 days after entry, and on the 11th day began a sharp decline that has lasted into the 7th day, when I exited. Implied volatility stood at 34.0% at exit, down 16.7 points from the entry level.

Shares rose by a net 0.3% over 24 days, or a +5% annual rate. The options position produced a 10.1% return for a +154% annual rate.


I have entered a short iron condor spread on XLY, using options that trade for the last time 45 days hence, on February 21. The premium is a $0.87 credit and the stock at the time of entry was priced at $125.93.

The profit zone for this position is between $130.87 on the upside and $117.87 on the downside.

The implied volatility rank (IVR) stands at 50.7%.

Premium: $0.87 Expire OTM
XLY-iron condor Strike Odds Delta
Long 132.00 87.0% 12
Break-even 130.87 81.5% 17.5
Short 130.00 76.0% 23
Puts
Short 121.00 77.0% 23
Break-even 117.87 82.5% 17.5
Long 117.00 88.0% 12

The premium is 29.0% of the width of the position’s wings.

The profit zone covers a 3.9% move to the upside and a 6.8% move to the downside of the entry price, for total coverage of 10.8%

The risk/reward ratio is 2.4:1, with maximum risk of $213 and maximum reward of $87 per contract.

By Tim Bovee, Portland, Oregon, January 7, 2020

Read More »

Live: Tuesday, December 7, 2019

2 p.m. New York time

I’ve updated the list of shares trades at the bottom of this post with results analysis for the positions I exited.

1:40 p.m. New York time

I’ve entered a short iron condor position on EEM. That completes my entry into options positions using puts and calls that expire on February 21. Next step is to update the stock trades I posted this morning with the results analysis for positions I exited.

1:25 p.m. New York time

FXE is a pass. Given the prices and strikes on the grid, the best I can do is a premium that is 20% of the average width of the iron condor’s wings. That’ not enough potential win to make up for the risk.

1:20 p.m. New York time

The XLI trade wraps up the 30%+ IVR prospects. Some of the positions I entered earlier have already seen a rope implied volatility, a good thing for a short iron condor position. I have two possibilities in the IVRU 25% to 29% range: FXE and EEM. The FXE fund tracks the Euro, and EEM is foreign markets. I’ll analyze both, and then that will be a wrap for the options.

1:15 p.m. New York time

I’ve entered a short iron condor position on XLI.

12:05 p.m. New York time

I’ve entered a short iron condor position on XBI.

That wraps up my prospects with an implied volatility rank of 30% or greater. After a breakfast break, I’ll see what’s attractive down to an IVR of 25%.

11:50  a.m. New York time

I’ve entered a short iron condor position on XLV.

The next down on the implied volatility rank list is USO, which is oil. I’m going to pass, given the uncertainties in the Middle East.

11:35 a.m. New York time

I’ve entered a short iron condor position on TLT.

11:20 a.m. New York time

I’ve entered a short iron condor position on GLD.

11:05 a.m. New York time

I’ve entered a short iron condor position on XLY, expiring in February.

10:40 a.m. New York time

This is entry day in my options cycle, the day I open short iron condor positions using options that expire on February 21. The routine of the cycle goes like this: Enter 45 days before expiration, sell at 50% of maximum potential profit, sell the remaining profitable positions 21 days prior to expiration (January 21), and hang on to the unprofitable positions until the turn profitable or until the are close to expiration.

The entry is complicated by one remaining unprofitable position built from the XLY options that expire  January 17. It is within the profit zone, but is not yet profit, and so I am hanging on to it, although it soaks up cash that might be used profitably for February expirations.

In stocks, the Zacks algorithm wiped out all but one of my Momentum holdings, although three found spots on the Bench because of their “strong buy” rating and one was added to the Growth Portfolio, which also saw three more additions.

Given the magnitude of the changes, I’ve tightened the Bench rules to allow only stocks with a #1 ranking from Zacks in order to free funds for the additions.

In the Genetics Portfolio, one is out, two  are in.

The trades and transfers (I’ll add results analysis of the exits later today):

  • Growth
    • Exits
      • NSIT for a $71.51 credit, up $0.06 from the entry price, producing a 14.5% return over 61 days for a +87% annual rate.
      • TX, a $21.44 credit, down 79 cents from entry. The exit resulted in a -3.6% loss over one days, or a -1,297% annual rate.
    • Entries
      • AMED for a $167.48 debit
      • LHCG, a $137.50 debit
      • MKSI, a $106.99 debit
    • Transfers in
      • FORM, from the Momentum Portfolio
  • Momentum
    • Exits
      • ACA for a $45.37 credit, up 4 cents from the entry price, resulting in a +0.1% return over one day for a +32% annual rate.
      • MBT, a $10.38 credit, up 2 cents from entry producing a 0.2% return over one day for a +70% annual rate.
    • Entries
      • ENPH, a $28.83 debit
      • ESTE, a $7.03 debit
      • HELE, a $182.18 debit
      • PFGC, a $52.10 debit
      • SYNA, a $69.55 debit
      • TALO, a $30.99 debit
    • Transfers in
      • CNXM duplicates a Growth Portfolio holding.
    • Transfers out
      • FORM, to the Growth Portfolio
      • DQ, JD and NGLOY to the Bench
  • Genetics
    • Exit
      • GH for a $78.80 credit, down $3.86 from the entry price. The decline was a $4.7% loss over 18 days, or a -95% annual rate.
    • Entries
      • CLLS for a $16.74 debit
      • INO, a $3.12 debit
  • Bench
    • Exits
      • OESX for a $3.37 credit, a 12-cent gain over the entry price, showing a $3.7% return over 12 days for a +112% annual rate.
      • BMY, a $63.28 credit, which is 46 cents below what I paid at entry, resulting in a -.7% loss over 21 days, or a -13% annual rate.
      • LPLA, a $93.59 credit, up 82 cents from entry, producing a 0.9% return over four das for a +81% annual rate.
    • Transfers in
      • BYD, STM from Growth; DQ, JD, NGLOY from Momentum

By Tim Bovee, Portland, Oregon, January 7, 2020

Read More »

Live: Monday, January 6, 2020

10:25 a.m. New York time

Options

My primary concern continues to be my short iron condor options position on XLY. It expires at the end of next week, it’s underlying stock price remains in the profit zone, and yet the positions remains unprofitable.

On Tuesday of this week — tomorrow — I enter new options positions using the series that expires February 21, which will be 45 days away. Earlier I posted about the shortage of exchange-traded funds with sufficient volatility to meet my standards for an options trade. Happily for my strategy, the situation has reversed, and I have ETFs in 10 different sectors that meet my standards: An implied volatility rank of 25% or higher.

I discussed  in an earlier post the possibility of using calendar spreads as a vehicle for trading low-volatility options positions. It’s the less desirable options compared to short iron condors, so now that my choices are greater, I shall slide calendar spreads back on  the shelf until the next low-vol period hits.

Stocks

In stocks, I have no exits planned today. Three stocks fell short of the metrics needed to remain in their portfolios: LPLA in the Growth Portfolio and PAAS in Momentum, both of them strategy portfolios, and BMY from Genetics, a watchlist portfolio. The strategy-based holdings were removed because of their metrics; the watchlist holdings was removed by managers of the ETF whose holdings list I’m using for my pool, ARKG.

All three continue to carry attractive ranks from Zacks, so I have moved them to the Bench, a portfolio for, among other uses, stocks that have been dropped from a portfolio that still have a buy (2) or strong buy (1) rank.

Three stocks joined the qualifying symbols in the Growth Portfolio: BYD, STM and TX.

I also added four positions to the Momentum Portfolio as I continue to move toward the goal of holding every stock in its population, which presently numbers 12. These trades put me more than halfway there, with five more to go. (The population changes every day, of course, so the goal is always in flux.)

The entries:

  • Growth
    • BYD for a $29.27 debit.
    • STM, a $26.73 debit.
    • TX, a $22.23 debit.
  • Momentum
    • ACA for a $45.33 debit.
    • FORM, a $26.09 debit.
    • JD, a $37.81 debit.
    • MBT, a $10.36 debit.

Over the weekend I implemented my decision to narrow the floating stop loss on all stock positions to 10%, improving the risk/reward ratio.

By Tim Bovee, Portland, Oregon, January 6, 2020

Read More »

Live: Friday, January 3, 2020

3:35 p.m. New York time

In light of the global economic uncertainties after recent events in the Middle East, I plan to reduce my my stop/losses to a trailing 10% over the weekend. Presently, they’re at a trailing 20%.

Here’s the portfolio inventory to end the week:

Options: XLY (a short iron condor)

Stocks:

  • Growth: ATSG, CNXM, HII, LAWS, LPLA, NSIT, RH and TLYS.
  • Momentum: DQ, NGLOY, PAAS and VIPS.
  • Genetics: AAPL, AQB, BMY, CGEN, GH and PSTI.
  • Income: HYG.
  • Bench: JNCE and OESX.

1 p.m. New York time

My short iron condor options position on XLY continues to be unprofitable, trading now at $0.90, well above my minimally profitable target of $0.44. Even so, the price remains within the profit zone, and so the odds are in favor of a profitable outcome. The position ends on January 17, and I shall continue to hold until next week

In stocks, the raging torrent of analyst reassessments continued, triggering three exits from the Growth Portfolio and two from the Genetics Portfolio.

Not all changes were negative. The algorithm added five new prospects to the Growth Portfolio.

I also added three symbols to the Momentum Portfolio. Yesterday’s exit from DX late in the session freed sufficient cash for me to fully build out the Momentum Portfolio, promoting from secondary status to a primary portfolio, on a par with Growth. For that purpose, I tightened the criteria for inclusion, the theory being that momentum varies far more quickly than value or growth, and so should have strict entrance requirements.

The good news is that there are only 14 positions in the reworked Momentum Portfolio, The bad news is that only one of my current momentum holdings, PAAS, still qualifies under the tighter rules. The other two, JNCE and OESX, continue to have strong buy rank from Zacks, so I’ll move them into the Bench Portfolio and continue to hold them until they drop down to a neutral rank.

This adds a second fully realized strategy to the mix, providing greater diversification of my holdings, always a good thing in my book.

The trades:

  • Exits
    • Growth Portfolio
      • AOSL for a $13.61 credit, up 2 cents from the entry price. The position returned 0.2% over three days for an 18% annual rate.
      • BLDR for a $25.31 credit, down 10 cents from the entry price, producing a 0.4% loss over one day, a -144% annual rate.
      • IBP for a $69.36 credit, down $2.14 from entry, showing a -3.0% loss over 22 days for a -50% annual rate.
    • Genetics Portfolio
      • CLLS for a $17.53 credit, down 86 cents from the entry price, producing a -4.7% loss over eight days, or a -14% annual rate.
      • CSTL for a $34.26 credit, up $7.20 from entry for a +26.6% return over 16 days, a 607% annual rate.
  • Entries:
    • Growth Portfolio
      • ATSG for a $23.17 debit
      • CNXM, a $17.79 debit
      • HII, a $258.94 debit
      • LAWS, a $52.53 debit
      • LPLA, a $92.77 debit
    • Momentum Portfolio
      • DQ for a $54.71 debit
      • NGLOY, a $14.44 debit
      • VIPS, a $14.99 debit

That’s the lot. A busy morning, and fine example of the new capabilities that come from no-commission trading. I did in a couple of hours what an exchange-traded fund or mutual fund might take days to accomplish. Their business models force them to think big, and that lengthens their response time. With no commission, I can respond quickly to the changing situation, keeping my positions manageably small so no one company’s ill fortune can cost me a significant portion of my trading funds. Thinking of it that way, it was a very good morning indeed.

By Tim Bovee, Portland, Oregon, January 3, 2020

Read More »

Live: Thursday, January 2, 2020

4:10 p.m. New York time

I exited DX for $16.88 credit, up $1.05 from the entry price. With 30 cents a share in dividends added in, the position produced a  6.5% return over 57 days for a +41% annual rate.

3:45 p.m. New York time

One of my Income Portfolio holdings, DX, has been downgraded to hold, and I’ve exited. Results shortly.

10:50 a.m. New York time

And once again a string of exits, two from my primary portfolio, Growth; one from a secondary portfolio, Momentum; and one from a watchlist portfolio, Genetics.

That follows five portfolio exits on December 31, two of them from Growth; one on December 30, from Growth; one on December 27, from Momentum; and three on December 26, two of them from Growth. That follows a period when exits from the Growth portfolio, while not rare, weren’t daily occurrences and didn’t come in batches. So what gives?

The Growth Portfolio differs from the other two strategy portfolios in that it is forward looking. It is based on analyst assessments of future prospects for earnings growth, the engine that drives stock prices. Momentum, in contrast, looks to the past — if the trend has been up in several different time frames the it qualifies for the portfolio. Value is wishful thinking — a stock is cheap now compared to earnings, maybe it will recover.

My hypotheses is that we’re getting a string revised assessments from analysts. It’s the start of the year, and that’s when such things happen. The next earnings season kicks off January 15, when AA publishes 4th quarter results, and it is in the run-up to earnings that new analytical reports are most useful.

Today’s trades in stocks.

  • Exits
    • Growth Portfolio
      • CRAI for a $53.94 credit, up $3.13 from entry. I received 23 cents in dividend payouts. Altogether, the position produced a 6.1% return over 43 days for a +52% annual rate.
      • HA for a $29.73 debit, down 93 cents from entry, resulting in a 3.0% loss over nine days, or a -123% annual rate.
    • Momentum Portfolio
      • IRWD for a $13.33 credit, down 12 cents from entry, showing a 0.9% loss over three days for a -109% annual rate.
    • Genetics Portfolio
      • EDIT for a $29.17 credit, down 53 cents from entry, producing a 1.85 loss over two days, or a -326% annual rate.
  • Entry
    • Growth Portfolio
      • BLDR for a $25.41 debit.

By Tim Bovee, Portland, Oregon, January 2, 2020

Read More »

Tuesday, December 31, 2019

12:10 p.m. New York time

A busy morning in my stock portfolios, with six exits and three entries. To me it suggests that the markets are churning at a top, leading to a downward correction, big or small.

Today’s trades:

  • Exits
    • Value Portfolio: PWR for a $40.82 credit, up 45 cents per share from entry, showing a 1.1% return over 22 days for a +19% annual rate.
    • Growth Portfolio
      • DCO for a $50.25 credit, up $1.77, producing a 3.7% return over 39 days for a 34% annual rate
      • MOMO for a $33.84% credit, down 3.51 from entry, a 9.4% loss over 29 das for a -118% annual rate.
    • Momentum Portfolio: CROX for a $41.92 credit, up 69 cents, showing a 1.7% return over four days for a 154% annual rate
    • Genetics Portfolio:
      • INCY for a $35.05 credit, down $4.51, producing a 4.9% loss over 14 days for a -128% annual rate.
      • NTLA for a $14.65 credit, down 57 cents, resulting in a 3.8% loss over 12 days for a -114% annual rate.
  • Entries
    • Growth Portfolio: AOSL, a $13.59 debit.
    • Genetics Portfolio:
      • AAPL, a $291.90 debit.
      • EDIT, a $29.70 debit.

So three losses, three wins on the exits.

By Tim Bovee, Portland, Oregon, December 31, 2019

Read More »

Live: Monday, December 30, 2019

11:45 a.m. New York time

I’ve entered a position on IRWD in the Momentum Portfolio, for a $13.45 per share debit.

11:15 a.m. New York time

SSD dropped off of the Growth Portfolio screen, and I exited for an $80.30 credit, a loss of $3.10 per share. The position produced a 3.7% loss over 59 days, or a -23% annual rate. It peaked six days after entry and swung into a slow decline.

By Tim Bovee, Portland, Oregon, December 30, 2019

Read More »

Trading Rules revisions

With the New Year rapidly approaching, I’ve redone my Trading Rules linked to on the top menu bar so that they match the practices I’ve developed over the fall and the first week of winter. They seem to have stabilized at this point; I can’t see any changes that I want to make immediately, although that’s not a promise for the future. Here are the new rules: Options first, then stocks. Enjoy.


Levels of Risk

Risk is everywhere. There is, in reality, nowhere without risk. Every thought can trigger risk. Every act can be risky. Every result, happy or sad, is a balance between risk and reward.

Keeping risk in mind, I have divided my holdings into three levels: No risk, low risk, mid-risk, and high risk. See the About page for more.

For any trade, low risk to high risk, there are two rules that rule them all:

  1. Have a defined rule for entering a position.
  2. Have a defined rule for exiting a position.

I’ve traded outside of those universal rules on occasion, and have always regretted it.

Outside of the two universal rules, only the mid-risk and high-risk positions have formal rulesets, and those are what I shall discuss here:

  1. High Risk: Options Contracts
  2. Mid-Risk: Momentum Trades of Shares
  3. Mid-Risk: Managed Shares

 

High Risk: Options Contracts

My options trading rules are straight out of research conducted by Tom Sosnoff‘s Tastytrade financial network, with the exception of the exits rules, where I’ve expanded on his methods. The rules are intended for smaller accounts, and has the goal of many base hits rather than the occasional home run amid a lot of strikeouts.

Trading Rules

Positions: Short vertical or iron condor spread.

  • Set the short leg or legs someone from delta 16 to 30. The higher the delta, the greater the risk and the smaller the odds of success.
  • Select an underlying stock whose Implied Volatility Rank (IVR) is 25% or greater. The higher the IVR, the greater the potential return. (This is similar to the IV Percentile found on many trading platforms.)
  • Set the width of the wings so as to be as close as possible to a third of the credit received.

Entry timing: As close as possible to 45 days prior to expiration, giving preference to monthly options. Generally, I won’t enter after 43 days prior to expiration.

Due diligence before entry:

  • Avoid earnings announcements
  • Avoid ex-dividend days
  • Ensure that the potential loss is within the trader’s guidelines for managing trading funds.

Exit rules:

  • Up to 21 days prior to the options expiration
    • Profitable trades:
      • Exit at 50% of maximum potential profit, calculated as this way:
        • (credit_received – current_debit) / credit_received
        • where credit received is maximum potential profit and current debit is the cost of exiting the position. If it’s negative, the position is a losing one at present.
  • 21 days or fewer prior to the options’ expiration
      • Exit if the position is profitable, even if minimally so
      • Hold an unprofitable position until
        • It becomes profitable, even minimally so, or
        • It expires unprofitably.

 

Mid-Risk: Share Trades

This strategy relies on a rule-based evaluation for the selection of stocks and on a 20% trailing stop/loss for the exit signal.

I divide my holdings and trading decisions into portfolios, depending upon the method used to evaluate potential additions.

My portfolios are divided into two sorts.

Strategy portfolios use a search of a category of stocks for a symbol that meets certain criteria corresponding with a strategy. I have three strategies that I use:

  • Growth, which relies on ratings changes given my market analysts.
  • Momentum, which relies on the rate of change over several lengths of time.
  • Value, which relies on the financial performance of the company compared to the price of its stock.

A second sort of portfolio, a watchlist portfolio, takes a relatively small list of stocks and trades those that meet general criteria according to one system or another.

At present I have only one such portfolio: Genetics. It was constructed based on the ARKG exchange-traded funds holdings.

Depending upon the rules, all of this can be done by the trader without relying on the analysis of others. For convenience, I’ve chosen to rely on the analysis aggregator Zacks  to provide the ratings of stocks that I use in making decisions.

Zacks uses analyst ratings on their primary method, using earnings forecasts to select from their already screened pool. Their method boils everything down to a numerical rank: 1 for strong buy, 2 for buy, 3 for neutral, 4 for sell and 5 for strong sell. The rating is relative: The top 5% of their stock pool gets a 1 ranks, as does the bottom 5%. The 2 and 4 ranks each get 15% of the pool, and the 3 rank gets the remaining 60%. So the ranks aren’t objectively good or bad, but only in relation to the rest of the approximately 10,000 stocks the company tracks.

For my strategy portfolios, I require that stocks have a Zacks rank of 1 for entry, and I exit that day if it drops away from the strong buy level. For my watchlist portfolios, I’ll requires a Zacks 1 or 2 rank for entry, with exit rules if that changes to a neutral or sell rank.

Upon buying the stock, set a trailing stop/loss for 20% below the fill price as the condition for exit. 

The stop/loss rule was based on three research papers:

Han, Yufeng and Zhou, Guofu and Zhu, Yingzi, Taming Momentum Crashes: A Simple Stop-Loss Strategy (September 24, 2016). Available at SSRN: https://ssrn.com/abstract=2407199 or http://dx.doi.org/10.2139/ssrn.2407199

Yusupov, Garib and Shorrason, Bergsveinn, Performance of Stop-Loss Rules vs. Buy-and-Hold Strategy (2009). Available at Lund University: https://www.lunduniversity.lu.se/lup/publication/1474565

Kaminski, Kathryn and Lo, Andrew W., When Do Stop-Loss Rules Stop Losses? (January 3, 2007). EFA 2007 Ljubljana Meetings Paper. Available at SSRN: https://ssrn.com/abstract=968338 or http://dx.doi.org/10.2139/ssrn.968338

The Zacks rank method presents trades almost every day, as stocks fail to qualify and new stocks qualify to take their place. A no-commission brokerage, which includes the pioneering Robinhood and the major brokerages such as E-Trade and TD Ameritrade that have followed in Robinhood’s footsteps, makes such rapid trading possible. A brokerage that charges commissions would require a different approach.

Zacks makes its ranks for individual stocks freely available, and that is sufficient for managing a small watchlist portfolio.

For example, in creating my Genetics Portfolio, I took the holdings of the ARKG exchange-traded fund — 37 stocks — and within Zacks created a portfolio containing those symbols. The portfolio includes up-to-date rankings for each symbol. Just by pulling up the portfolio and sorting on rank, I can instantly see what the tradable stocks are and compare it with what I already hold. At this writing I hold all nine qualifying stocks.

For my strategy portfolios, which scans the entirely of the massive Zacks stock pool, it’s necessary that I be able to run queries against their databased, and for that I need a premium account, costing an annual subscription of $249. Traders with small accounts will do better by using the watchlist method, thereby avoiding the overhead.

The subscription works out to $20.75 a month, and I’ve entered about 30 positions in the current month, so divide by 60 — once for entry and again for exit — and it works out to a 35 cent premium per trade. Not such a bad deal, considering that in the bad old days of last spring, the commissions would have been at least $13 total for each position.

By Tim Bovee, December 28, 2019, Portland, Oregon

Read More »

Live: Friday, December 27, 2019

3:05 p.m. New York time

A holdings inventory:

  • Options
    • Short iron condor XLY
  • Shares portfolios:
    • Strategy
      • Growth CRAI, DCO, HA, IBP, MOMO, NSIT, RH, SSD, TLYS
      • Momentum CROX, JNCE, OESX, PAAS
      • Value PWR
      • Income DX, HYG
    • Watchlist
      • Genetics AQB, BMY, CGEN, CLLS, CSTL, GH, INCY, NTLA, PSTI

2:50 p.m. New York time

I found some spare change that I used to add CROX to my Momentum Portfolio, for a $41.23 debit.

11:30 a.m. New York time

I’ve updated my TLT analysis with results.

11:10 a.m. New York time

No stock trades today.

10:50 a.m. New York time

Today is management day for the JAN monthlies, 21 days before the January 17 expiration.

I exited my short iron condor position on TLT at 50.7% of maximum potential profit, a bit more than my 50% target. My short iron condor position on XLY remains unprofitable, so I’ll continue to hold it, exiting at the first sign of profit, no matter how small.

I’ll post the TLT results in detail later this morning.

By Tim Bovee, Portland, Oregon, December 27, 2019

Read More »

Live: Thursday, December 26, 2019

10:15 a.m. New York time

And the trades are done:

  • Growth Portfolio
    • Exited
      • FCN for a $110.83 credit, up 91 cents, a 0.8% return over 29 days for a +10% annual rate.
      • WGO for a $52.67 credit, down 37 cents, a 0.7% loss over 36 days for a -7% annual rate.
  • Genetics Portfolio
    • Exited
      • EDIT for a $32.36 credit, down 5 cents, a 0.2% loss over two days for a -28% annual rate.
    • Entered
      • CLLS for an $18.39 per share debit.
      • PSTI for a $3.95 debit.
  • Momentum Portfolio
    • Entered
      • JNCE for a $9.55 debit
      • OESX for a $3.25 debit
      • PAAS for a $3.95 debit

So, total score, 3 out, 5 in for a total of 8 trades in 45 minutes. Not that anyone’s counting.

9:25 a.m. New York time

In stocks, Zacks’ algorithm dropped FCN in the Growth Portfolio to hold (rank 3), WGO also was removed from the screen, and I shall exit both. In the Genetics Portfolio, EDIT also dropped. Neither shows in the secondary portfolios (Momentum and Value), so away they go.

I shall enter two positions in the Genetics Portfolio, CLLS and PSTI, completing the build out. Also, with the Growth Portfolio build out complete, I’m starting fill the Momentum Portfolio, beginning with NCE, OESX and PAAS.

I’ve posted some thoughts on portfolio-building in the new era of no commissions: DIY ETF.

By Tim Bovee, Portland, Oregon, December 26, 2019

Read More »